ClinicalTrials.gg
CompletedNCT00259402Updated Dec 7, 2009

Oxaliplatin in Esophagus Cancer (Advanced) 1st Line

A Phase 2 interventional study of Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU) in Esophageal Neoplasms, sponsored by Sanofi. Completed at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2009-12-07.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing fluorouracil in Esophageal Neoplasms — 1 open to participants now, 3 under way, 1 of them phase 3. Fluorouracil · Esophageal Neoplasms.

Enrollment
25th of 49
41 · median 41
Started
2000
with 6 others
Phase 2
29 of 54
1 open now
Registered
24th of 54
by date

Among the 54 studies testing fluorouracil in Esophageal Neoplasms, this one is the 25th largest by enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2000, is one of 29 in phase 2, and was the 24th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

1 of the 54 studies testing fluorouracil in Esophageal Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing fluorouracil in Esophageal Neoplasms, or all of them as a file.
02

Study summary

  • To determine the activity and efficacy of the schema specified as dose regimen
  • To determine the safety and tolerability of the oxaliplatin-cisplatin and 5FU
03

Conditions studied

  • Esophageal Neoplasms
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 0-1
  • Patients with proven epidermoid carcinoma or adenocarcinoma of esophagus or stomach, with unresectable or disease;
  • No previous treatment with chemotherapy or radiotherapy
  • (uni or bidimensional)

Exclusion criteria

Exclusion Criteria:

  • Creatinin clearance \<50 mL/min
  • Total >1.5* (Upper Limit of Normal)
  • /ALT > 2.5*ULN
  • Total White Blood Cell \<1.500.000/mL
  • count \<100.000.000/mL
  • symptomatic sensitive peripheral neuropathy
  • pregnant or breast-feeding women

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Oxaliplatin

    Drug: Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)

Interventions

  • DrugOxaliplatin + cisplatin + 5-Fluorouracil (5-FU)

    Drug page: Fluorouracil

    OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy

06

What researchers measure

Primary outcomes

  1. Efficacy endpoints include tumor response, progression free and overall survival.

    Time frame: Throughout the whole study

Secondary outcomes

  1. Safety endpoints include summary of adverse events assessed by history, physical exams and laboratory evaluations.

    Time frame: Throughout the whole study duration

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2000, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2005
First posted
Nov 29, 2005
Start
Feb 2000
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Last update
Dec 7, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00259402
Lead sponsor
Sanofi
First posted
Nov 29, 2005
Start date
Feb 2000
Primary completion
Oct 2008
Completion
Oct 2008
Last update
Dec 7, 2009

Study contacts

José Mª Taboada
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluorouracil

Start the discussion